Life-changing therapies to help people build families and live better lives
At Ferring, we are committed to helping people build families and live better lives. In the United States, Ferring is a leader in reproductive medicine, uro-oncology and in specialty areas within orthopaedics, and gastroenterology, including microbiome therapeutics.
Believing in the power of research
Each of us at Ferring contribute to providing innovative solutions to help people live better lives. We devote significant research and development investment to new therapeutics, life cycle management and next generation healthcare solutions.
Join us
At Ferring Pharmaceuticals we highly value an attractive working environment that motivates our employees and stimulates the creative abilities and initiative of both individuals and teams. With over 6,000 employees in more than 50 countries, we are able to draw upon a large multicultural setting to enrich the work of our staff on all levels.
Helping people live better lives
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives.
Ferring is a leader in reproductive medicine, uro-oncology and in specialty areas within orthopaedics, and gastroenterology, including microbiome therapeutics.
News
-
Ferring Highlights New Real-World Research with ADSTILADRIN® (nadofaragene firadenovec-vncg) in Clinical Practice
-Three abstracts to be presented at the 101st Annual Meeting of the Western Section of the American Urological Association, including baseline characteristics and demographics for patients enrolled ...
-
Ferring Pharmaceuticals Presents Two New Analyses of Pivotal Trial Data for Follitropin Delta (FE 999049) at ASRM 2025
-Analyses from the two Phase 3 RITA trials evaluate both the suitability of age-based dosing as well as the tolerability of treatment with follitropin delta in women undergoing controlled ovarian st...
-
Ferring Presents New Data Analyses for REBYOTA® (fecal microbiota, live – jslm) at ACG 2025
-Oral presentation highlights microbiome restoration through six months with REBYOTA from Phase 3b CDI-SCOPE trial New data from CDI-SCOPE evaluating the long-term safety of REBYOTA Retrospective an...